

Application No. 10/510,119
Paper Dated: January 10, 2008
In Reply to USPTO Correspondence of September 10, 2007
Attorney Docket No. 0470-045183

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claims 1-12. (Cancelled)

Claim 13 (Currently Amended): A method for treating a tumor or infectious agent in a subject, wherein an effective amount of an agonistic anti-CD40 antibody, or a fragment thereof which stimulates the CD40 receptor is administered to the subject for induction of systemic T cell immunity against an antigen of the tumor or infectious agent, and wherein the treatment does not comprise immunization with an antigen of the tumor or infectious agent.

Claim 14 (Currently Amended): The method according to claim 13, wherein the tumor or infectious agent does not express the CD40 receptor.

Claim 15 (Currently Amended): The method according to claim 13, wherein the CD40 receptor targeted by the agonistic anti-CD40 antibody or fragment thereof which stimulates the CD40 receptor is expressed on dendritic cells of the treated subject.

Claim 16 (Previously Presented): The method according to claim 13, wherein the induced systemic T cell immunity is a cytotoxic T cell response.

Claim 17 (Currently Amended): The method according to claim 13, wherein the agonistic anti-CD40 antibody or fragment thereof which stimulates CD40 is human, humanized, chimeric or deimmunized is such that the T and B cell epitopes have been eliminated.

Claim 18 (Currently Amended): The method according to claim 13, wherein the fragment is a V_H, V_L, Fv, Fd, Fab, (Fab)₂ (Fab')₂ or scFv fragment of a human antibody and said fragment is used to produce a chimeric antibody, said chimeric antibody being able to stimulate CD40.

Application No. 10/510,119
Paper Dated: January 10, 2008
In Reply to USPTO Correspondence of September 10, 2007
Attorney Docket No. 0470-045183

Claim 19 (Currently Amended): The method according to claim 13, wherein the agonistic anti-CD40 antibody, or a fragment thereof which stimulates the CD40 receptor is administered to the subject by injection or oral administration.

Claim 20 (Currently Amended): The method according to claim 17, wherein the human, humanized, chimeric or deimmunized antibodies in which the T and B cell epitopes have been eliminated, all being agonistic anti-CD40 antibody is administered to the subject by injection or oral administration.

Claim 21 (Currently Amended): The method according to claim 18, wherein ~~the V_H, V_L, Fv, Fd, Fab, (Fab)₂ or scFv fragment of the human chimeric antibody~~ agonistic anti-CD40 antibody is administered to the subject by injection or oral administration.

Claim 22 (Previously Presented): The method according to claim 19, wherein the injection is an intra-tumoral injection.

Claim 23 (Previously Presented): The method according to claim 20, wherein the injection is an intra-tumoral injection.

Claim 24 (Previously Presented): The method according to claim 21, wherein the injection is an intra-tumoral injection.

Claim 25 (Previously Presented): The method according to claim 13, wherein the antigen is a tumor-specific antigen.

Claim 26. (Cancelled)